Is EBS or ETON more undervalued in 2026?

CirclFi compares Emergent BioSolutions Inc. (EBS) and Eton Pharmaceuticals, Inc. (ETON) using 13 institutional-grade valuation models. EBS has a Quality of Company score of 8.3/10 while ETON scores 6.5/10.

Which is a better buy — EBS or ETON?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do EBS and ETON valuations compare?

EBS at $9.18 and ETON at $31.86 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

EBS vs ETON Valuation Comparison 2026 — Intrinsic Value Analysis

EBS

Drug Manufacturers - Specialty & Generic

Emergent BioSolutions Inc.

Quality

8.3

out of 10

Value Trap

SAFE

Price

$9.18

Last close

Models

12/13

Active

ETON

Drug Manufacturers - Specialty & Generic

Eton Pharmaceuticals, Inc.

Quality

6.5

out of 10

Value Trap

SAFE

Price

$31.86

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	EBS Fair Value	EBS Upside	ETON Fair Value	ETON Upside
Bayesian DCF	Intrinsic	$25.49	+177.6%	$5.20	-83.7%
Earnings Power Value	Intrinsic	$52.15	+468.1%	$1.15	-96.4%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for EBS vs ETON — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EBS vs ETON — Which Stock Is More Undervalued?

EBS scores higher with a 8.3/10 quality rating vs ETON's 6.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Emergent BioSolutions Inc. (EBS) and Eton Pharmaceuticals, Inc. (ETON) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EBS currently trades at $9.18 with a QOC of 8.3/10, while ETON trades at $31.86 with a QOC of 6.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).